|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute on Drug Abuse (NIDA) |
|---|---|
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00419731 |
Purpose
The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit.
| Condition | Intervention | Phase |
|---|---|---|
|
Tobacco Use Disorder |
Drug: Bupropion Drug: Bupropion + Naltrexone |
Phase II Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation |
| Estimated Enrollment: | 120 |
| Study Start Date: | November 2006 |
| Estimated Study Completion Date: | January 2010 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Active Comparator
Bupropion+Placebo
|
Drug: Bupropion
Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks. Placebo, 25 mg, q.d., for 7 weeks. |
|
2: Experimental
Bupropion+Naltrexone
|
Drug: Bupropion + Naltrexone
Bupropion, Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks. Naltrexone, 25 mg, q.d., for 7 weeks. |
The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit. Bupropion is an FDA-approved medication for smoking cessation that is believed to provide relief from craving and withdrawal through promotion of two neurotransmitter chemicals, dopamine and noradrenaline. Naltrexone is an FDA-approved medication for the treatment of opiate and alcohol dependence, that appears to function through blocking certain opiate receptors in the brain. It is expected that bupropion + naltrexone will produce higher smoking quit rates than bupropion + placebo. Bupropion alone is effective in alleviating some nicotine withdrawal complaints and craving for nicotine. However, bupropion does not reduce the rewarding effects of slips to smoking. Naltrexone alone is not generally effective as a smoking cessation medication, but it does help to reduce the rewarding effects of slips to smoking. Thus, it may help to prevent full relapse to smoking. In addition, naltrexone can help to reduce craving for cigarettes. It is hypothesized that the differing complementary actions of the two drugs will help smokers more than bupropion alone. In addition to examining smoking quit rates, the proposed study will also look at psychological processes that change during smoking cessation including, nicotine withdrawal, nicotine craving, mood, impulsivity, and attention
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Marc E Mooney, Ph.D. | 612-627-1822 | moon0078@umn.edu |
| Contact: Dorothy K Hatsukami, Ph.D. | 612-627-1808 | hatsu001@umn.edu |
| United States, Minnesota | |
| Tobacco Use Research Center, University of Minnesota | Recruiting |
| Minneapolis, Minnesota, United States, 55414 | |
| Contact: Marc E Mooney, Ph.D. 612-627-1822 moon0078@umn.edu | |
| Principal Investigator: Marc E Mooney, Ph.D. | |
| Principal Investigator: | Marc E Mooney, Ph.D. | Univerisity of Minnesota |
More Information
| Responsible Party: | University of Minnesota ( Marc E. Mooney, Ph.D. ) |
| Study ID Numbers: | K01-DA019446-01, K01 DA019446-01, DPMCDA |
| Study First Received: | January 8, 2007 |
| Last Updated: | May 12, 2009 |
| ClinicalTrials.gov Identifier: | NCT00419731 History of Changes |
| Health Authority: | United States: Federal Government; United States: Institutional Review Board |
|
nicotine smoking addiction |
|
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Tobacco Use Disorder Narcotic Antagonists Physiological Effects of Drugs Psychotropic Drugs Disorders of Environmental Origin Pharmacologic Actions Mental Disorders |
Sensory System Agents Therapeutic Uses Naltrexone Bupropion Substance-Related Disorders Dopamine Agents Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |